From Yahoo Finance: 2025-06-11 08:03:00

President Trump’s regulations to boost US pharmaceutical manufacturing face uncertainty, with questions over implementation. Executive orders target drugmakers to increase US manufacturing, including prioritizing FDA approval for domestic facilities. Critics question the lack of clarity and effectiveness of the policy, as the industry remains sceptical. However, big pharma companies like Johnson & Johnson, Roche, Novartis, Eli Lilly, and Genentech are investing billions in US facilities, creating thousands of jobs. The investments reflect a trend to strengthen domestic operations amidst geopolitical pressures. The future of tariffs on imported pharmaceuticals may be influenced by these significant investments in the US.



Read more at Yahoo Finance: Trump’s push to onshore pharma manufacturing clouded by ‘lack of clarity’